P-gp Inhibitors: A Potential Tool to Overcome Drug Resistance in Cancer Chemotherapy

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Unknown venue

• Publication date

  2016-03-28

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1201/B19867-9
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Mammalian drug efflux transporters of the ATP binding cassette (ABC) family

  2012cited by this paper
• Revisiting the ABCs of multidrug resistance in cancer chemotherapy.

  2011cited by this paper
• The P-glycoprotein multidrug transporter.

  2011cited by this paper
• P-glycoprotein inhibition: the past, the present and the future.

  2011cited by this paper
• Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer.

  2011cited by this paper
• Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics.

  2010cited by this paper
• Membrane transporters in drug development

  2010cited by this paper
• A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer

  2010cited by this paper
• Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors.

  2010cited by this paper
• Characterization of an Asymmetric Occluded State of P-glycoprotein with Two Bound Nucleotides

  2010cited by this paper
• Herb–Drug Interactions with St John’s Wort (Hypericum perforatum): an Update on Clinical Observations

  2009cited by this paper
• Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.

  2009cited by this paper
• A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine

  2009cited by this paper
• ABC multidrug transporters: structure, function and role in chemoresistance.

  2008cited by this paper
• Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition

  2008cited by this paper
• Hyaluronan-CD44 Interaction Activates Stem Cell Marker Nanog, Stat-3-mediated MDR1 Gene Expression, and Ankyrin-regulated Multidrug Efflux in Breast and Ovarian Tumor Cells*

  2008cited by this paper
• ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra?

  2007cited by this paper
• A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX‐710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer

  2007cited by this paper
• Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy

  2007cited by this paper
• Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system.

  2006cited by this paper
• Structure, Function, Expression, Genomic Organization, and Single Nucleotide Polymorphisms of Human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux Transporters

  2006cited by this paper
• Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.

  2006cited by this paper
• Targeting multidrug resistance in cancer

  2006cited by this paper
• Phase III study of PSC‐833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95)

  2006cited by this paper
• Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.

  2006cited by this paper
• Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.

  2005cited by this paper
• Transmembrane inhibitors of P-glycoprotein, an ABC transporter.

  2005cited by this paper
• In vivo RNA Interference–Mediated Ablation of MDR1 P-Glycoprotein

  2005cited by this paper
• Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar

  2005cited by this paper
• Inhibitors of multidrug efflux transporters: their membrane and protein interactions.

  2005cited by this paper
• ABC transporters in the balance: is there a role in multidrug resistance?

  2005cited by this paper
• P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway.

  2005cited by this paper
• Do drug substrates enter the common drug-binding pocket of P-glycoprotein through "gates"?

  2005cited by this paper
• The effects of jatrophane derivatives on the reversion of MDR1- and MRP-mediated multidrug resistance in the MDA-MB-231 (HTB-26) cell line.

  2005cited by this paper
• Inhibitors of p-glycoprotein--lead identification and optimisation.

  2005cited by this paper
• Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection

  2005cited by this paper
• Vincristine induction of mutant and wild-type human multidrug-resistance promoters is cell-type-specific and dose-dependent

  2005cited by this paper
• Unmasking the dynamic interplay between efflux transporters and metabolic enzymes.

  2004cited by this paper
• Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.

  2004cited by this paper
• A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy

  2004cited by this paper
• Dexamethasone as a probe for docetaxel clearance

  2004cited by this paper
• Functional Implications of Genetic Polymorphisms in the Multidrug Resistance Gene MDR1 (ABCB1)

  2004cited by this paper
• Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies.

  2004cited by this paper
• Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides.

  2004cited by this paper
• Inhibition of multidrug resistance by immunisation with synthetic P-glycoprotein-derived peptides.

  2004cited by this paper
• Verapamil and Its Derivative Trigger Apoptosis through Glutathione Extrusion by Multidrug Resistance Protein MRP1

  2004cited by this paper
• MDR-1 C3435T Polymorphism Influences Cyclosporine A Dose Requirement in Liver-Transplant Recipients

  2004cited by this paper
• VX-710 (Biricodar) Increases Drug Retention and Enhances Chemosensitivity in Resistant Cells Overexpressing P-Glycoprotein, Multidrug Resistance Protein, and Breast Cancer Resistance Protein

  2004cited by this paper
• Herbal Modulation of P‐Glycoprotein

  2004cited by this paper
• Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults.

  2004cited by this paper
• Multidrug resistance reversal agents.

  2003cited by this paper
• Considerations in the design and development of transport inhibitors as adjuncts to drug therapy.

  2003cited by this paper
• Transcriptional regulation of ABC drug transporters

  2003cited by this paper
• Multidrug resistance: can new drugs help chemotherapy score against cancer?

  2003cited by this paper
• Blockade of G Protein-Coupled Receptors and the Dopamine Transporter by a Transmembrane Domain Peptide: Novel Strategy for Functional Inhibition of Membrane Proteins in Vivo

  2003cited by this paper
• The cyclosporin PSC 833 increases survival and delays engraftment of human multidrug-resistant leukemia cells in xenotransplanted NOD-SCID mice

  2002cited by this paper
• Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.

  2002cited by this paper
• The preferential induction of apoptosis in multidrug-resistant KB cells by 5-fluorouracil.

  2002cited by this paper
• Drug interaction studies between paclitaxel (Taxol) and OC144-093 — A new modulator of MDR in cancer chemotherapy

  2002cited by this paper
• Selective Inhibition of P-glycoprotein Expression in Multidrug-Resistant Tumor Cells by a Designed Transcriptional Regulator

  2002cited by this paper
• Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic.

  2001cited by this paper
• Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.

  2001cited by this paper
• A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.

  2001cited by this paper
• In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.

  2001cited by this paper
• The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux

  2001cited by this paper
• Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism.

  2000cited by this paper
• Development of Multidrug-Resistance Convertors: Sense or Nonsense?

  2000cited by this paper
• Regulation of the MDR1 gene by transcriptional repressors selected using peptide combinatorial libraries.

  2000cited by this paper
• Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration.

  2000cited by this paper
• P-Glycoprotein, a gatekeeper in the blood-brain barrier.

  1999cited by this paper
• Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells.

  1999cited by this paper
• Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG

  1999cited by this paper
• Inhibition of G-protein-coupled Receptor Function by Disruption of Transmembrane Domain Interactions*

  1999cited by this paper
• A mutation in the promoter of the multidrug resistance gene (MDR1) in human hematological malignancies may contribute to the pathogenesis of resistant disease.

  1999cited by this paper
• Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum.

  1998cited by this paper
• 2-Deoxy-D-glucose preferentially kills multidrug-resistant human KB carcinoma cell lines by apoptosis.

  1998cited by this paper
• Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge.

  1997cited by this paper
• MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine.

  1996cited by this paper
• Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs?

  1996cited by this paper
• Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.

  1996cited by this paper
• The human MDR3 P‐glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice

  1994cited by this paper
• Human P-glycoprotein transports cyclosporin A and FK506.

  1993cited by this paper
• Fluorescent cellular indicators are extruded by the multidrug resistance protein.

  1993cited by this paper
• Differential inhibition by cyclosporins of primary‐active ATP‐dependent transporters in the hepatocyte canalicular membrane

  1993cited by this paper
• Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein.

  1992cited by this paper
• Is the multidrug transporter a flippase?

  1992cited by this paper
• Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody.

  1992cited by this paper
• In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.

  1991cited by this paper
• Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

  1991cited by this paper
• Monoclonal Anti‐P‐glycoprotein Antibody‐dependent Killing of Multidrug‐resistant Tumor Cells by Human Mononuclear Cells

  1990cited by this paper
• P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance.

  1989cited by this paper
• Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

  1987cited by this paper
• Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.

  1987cited by this paper
• Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells.

  1986cited by this paper
• Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.

  1981cited by this paper

• Advanced Biopolymeric Systems for Drug Delivery

  2020cites this paper
• Emerging potential of niosomes in ocular delivery

  2020cites this paper
• Liposomes for Advanced Drug Delivery

  2020cites this paper
• Basics to advances in nanotherapy of colorectal cancer

  2019cites this paper
• Application Potential of Engineered Liposomes in Tumor Targeting

  2017cites this paper